Iopofosine I-131
- Generic Name
- Iopofosine I-131
- Drug Type
- Small Molecule
- Chemical Formula
- C29H53INO4P
- CAS Number
- 873438-88-1
- Unique Ingredient Identifier
- R048696O9L
- Background
Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05610891
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
CLR 131 Combined With Radiation for Head and Neck Cancer
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 12
- Registration Number
- NCT04105543
- Locations
- 🇺🇸
UW Cancer Center Johnson Creek, Johnson Creek, Wisconsin, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
- Conditions
- DIPGNeuroblastomaEwing SarcomaPediatric Solid TumorPediatric Brain TumorRhabdomyosarcomaOsteosarcomaPediatric Lymphoma
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03478462
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇦🇺Children's Hospital at Westmead, Westmead, New South Wales, Australia
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02278315
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Registration Number
- NCT01778088
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01495663
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Georgetown University Hospital, Washington, DC, District of Columbia, United States
Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2010-05-04
- Lead Sponsor
- Cellectar, Inc
- Target Recruit Count
- 9
- Registration Number
- NCT00925275
- Locations
- 🇺🇸
Georgetown University, Lombardi Cancer Center, Washington, District of Columbia, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.